Question 17971 — pharmacy and medicines

Summary

Ms. Agnès Firmin Le Bodo draws the attention of the Minister of Solidarity and Health to the development of biosimilar drugs in the city. Indeed, after the rise of generic drugs which has made it possible to save nearly 22 billion euros in 15 years, the first biosimilars of major biological drugs are available and a number of patents are preparing to enter the public domain in the coming months. These drugs, reliable and efficient, represent a tremendous source of savings: according to the Court of Auditors, more than 680 million euros for a current expenditure of nearly 1.5 billion euros per year. Thus the potential savings for social security, cumulative over the period 2019-2022 could amount to around 300 million euros, and this simply with the 5 most important biosimilars delivered mainly in cities already marketed or which will be marketed soon (Etanercept, Insulin Glargine, Enoxaparin, Pegfilgrastim, Adalimumab). These savings are unfortunately blocked by a certain number of legislative or regulatory obstacles, which must be urgently removed to preserve the French healthcare system and offer everyone access to innovative treatments. Even though the conditions defined by the social security financing law for 2014 are perfectly clear, the decree implementing the text relating to the planned substitution has still not been taken, more than five years after the text came into force. Thus, while the penetration dynamic of biosimilars in hospitals is strong, the development of these drugs remains weak in cities. The “My Health 2022” bill is an opportunity to respond to these blockages. It's on the triptych doctors-pharmacists-patients that will underpin the success of biosimilar drugs. Therefore, she asks him to please tell her what decisions will be taken soon in order to resolve this situation.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.